Zhanhu Zhang1, Wenjie Hu2, Linlin Li2, Hongxia Ding3, Haibo Li2. 1. Institute of Medical Genetics and Reproductive Medicine, Nantong Maternity and Child Health Hospital, Nantong, Jiangsu, China. 2. Department of Clinical Laboratory Medicine, Nantong Maternal and Child Health Hospital, Nantong, Jiangsu, China. 3. Pharmacodia (Beijing) Co., LTD, Beijing, China.
Abstract
BACKGROUND: We herein provide an overview of the clinical laboratory tests that should be performed before, during and after using therapeutic monoclonal antibodies (mAbs) and the clinical laboratory tests that may be affected by mAbs. METHODS: The labels of FDA-approved therapeutic mAbs were downloaded from DailyMed (the official website for drug labels) and were used as the sources of data for this review. RESULTS: It was found that most of the labels provided information relevant to the clinical laboratory tests, including the tests needed before mAbs treatment to check the patients' background status and to identify potentially sensitive patients, the tests needed during or after the treatment to evaluate the patients' response, and the mAbs that may lead to false positive or negative results for clinical laboratory tests. CONCLUSIONS: The present findings will be of interest to physicians, laboratory scientists, those involved in drug development and surveillance and individuals making health care policy.
BACKGROUND: We herein provide an overview of the clinical laboratory tests that should be performed before, during and after using therapeutic monoclonal antibodies (mAbs) and the clinical laboratory tests that may be affected by mAbs. METHODS: The labels of FDA-approved therapeutic mAbs were downloaded from DailyMed (the official website for drug labels) and were used as the sources of data for this review. RESULTS: It was found that most of the labels provided information relevant to the clinical laboratory tests, including the tests needed before mAbs treatment to check the patients' background status and to identify potentially sensitive patients, the tests needed during or after the treatment to evaluate the patients' response, and the mAbs that may lead to false positive or negative results for clinical laboratory tests. CONCLUSIONS: The present findings will be of interest to physicians, laboratory scientists, those involved in drug development and surveillance and individuals making health care policy.
Authors: Giuseppe Murdaca; Francesca Spanò; Miriam Contatore; Andrea Guastalla; Elena Penza; Ottavia Magnani; Francesco Puppo Journal: Expert Opin Drug Saf Date: 2015-11-11 Impact factor: 4.250
Authors: Gregory A Wiseman; Leo I Gordon; Pratik S Multani; Thomas E Witzig; Stewart Spies; Nancy L Bartlett; Russell J Schilder; James L Murray; Mansoor Saleh; Roberta S Allen; Antonio J Grillo-López; Christine A White Journal: Blood Date: 2002-06-15 Impact factor: 22.113
Authors: I R Badell; M C Russell; K Cardona; V O Shaffer; A P Turner; J G Avila; J A Cano; F V Leopardi; M Song; E A Strobert; M L Ford; T C Pearson; A D Kirk; C P Larsen Journal: Am J Transplant Date: 2012-03-28 Impact factor: 8.086
Authors: Marlies Oostendorp; Jeroen J Lammerts van Bueren; Parul Doshi; Imran Khan; Tahamtan Ahmadi; Paul W H I Parren; Wouter W van Solinge; Karen M K De Vooght Journal: Transfusion Date: 2015-05-18 Impact factor: 3.157
Authors: Christopher McCudden; Amy E Axel; Dominique Slaets; Thomas Dejoie; Pamela L Clemens; Sandy Frans; Jaime Bald; Torben Plesner; Joannes F M Jacobs; Niels W C J van de Donk; Philippe Moreau; Jordan M Schecter; Tahamtan Ahmadi; A Kate Sasser Journal: Clin Chem Lab Med Date: 2016-06-01 Impact factor: 3.694
Authors: Mascha Binder; Friederike-Nora Vögtle; Stefan Michelfelder; Fabian Müller; Gerald Illerhaus; Sangeeth Sundararajan; Roland Mertelsmann; Martin Trepel Journal: Cancer Res Date: 2007-04-15 Impact factor: 12.701
Authors: T Tajiri; H Matsumoto; Y Gon; R Ito; S Hashimoto; K Izuhara; M Suzukawa; K Ohta; J Ono; S Ohta; I Ito; T Oguma; H Inoue; T Iwata; Y Kanemitsu; T Nagasaki; A Niimi; M Mishima Journal: Allergy Date: 2016-05-17 Impact factor: 13.146